A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component

Pain

Volumn 157, Issue 7, 2016, Pages 1499-1507

  Atkinson, J Hampton ^a,b   Slater, Mark A ^a,c   Capparelli, Edmund V ^a,d   Patel, Shetal M ^a   Wolfson, Tanya ^e   Gamst, Anthony ^e   Abramson, Ian S ^e   Wallace, Mark S ^a,e   Funk, Stephen D ^a   Rutledge, Thomas R ^a,b   Wetherell, Julie L ^a,b   Matthews, Scott C ^a,b   Zisook, Sidney ^a,b   Garfin, Steven R ^a,e  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HonorHealth and the Scottsdale Lincoln Health Network   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analgesia; Anticonvulsants; Chronic back pain; Chronic pain; Clinical trial; Gabapentin

Indexed keywords

GABAPENTIN; PLACEBO; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ADULT; ANALGESIA; ARTICLE; BALANCE IMPAIRMENT; CONCENTRATION LOSS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; OSWESTRY DISABILITY INDEX; PAIN ASSESSMENT; PAIN INTENSITY; PARALLEL DESIGN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDAL IDEATION; TIME; VISUAL DISORDER; XEROSTOMIA; AGED; CHRONIC PAIN; DISABILITY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PAIN MEASUREMENT; TREATMENT OUTCOME;

ADULT; AGED; AMINES; ANALGESICS; CHRONIC PAIN; CYCLOHEXANECARBOXYLIC ACIDS; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84976415503     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000554     Document Type: Article

References (44)

1. Arnold LM, Goldenberg DL, Standord SB. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007; 56: 1336-44
2. Atkinson JH, Slater MA, Wahlgren DR, Williams RA, Zisook S, Pruitt SD, Epping-Jordan JE, Patterson TL, Grant I, Abramson I, Garfin SR. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. PAIN 1999; 83: 137-45
3. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-6
4. Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio: Psychological Corporation, 1996
5. Brown LD, Cai T, Zhou H. Nonparametric regression in exponential families. Ann Stat 2010; 38: 2005-46
6. Chou R, Huffman LH, American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147: 505-14
7. Cohen J. Statistical power analyses for the behavioral sciences (Rev Ed). New York: Academic Press, 1977
8. Davidson M, Keating JL. A comparison of five low back disability questionnaires: reliability and responsiveness. Phys Ther 2002; 82: 8-24
9. de C Williams AC, Davies HTO, Chadury Y. Simple pain rating scales hide complex idiosyncratic meanings. PAIN 2000; 85: 457-63
10. Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001; 344: 363-70
11. Doctor JN, Slater MA, Atkinson JH. The descriptor differential scale of pain intensity: an evaluation of item and scale properties. PAIN 1995; 61: 251-60
12. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60: 1274-83
13. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-21
14. Fairbank JCT, Pynsent PB. The oswestry disability index. Spine 2000; 25: 2940-53
15. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. PAIN 2001; 94: 149-58
16. FishbainDA, Cole B, Lewis JE, Gao J.What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med 2014; 15: 4-15
17. Gracely RH, Kwilosz DM. The Descriptor Differential Scale: applying psychophysical principles to clinical pain assessment. PAIN 1988; 35: 279-88
18. Guy W. Clinical global impression, ECDEU assessment manual for psychopharmacology. Washington: US Government Printing Office, 1976
19. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline, and their combination vs. placebo in patients with chronic lumbar root pain. PAIN 2007; 130: 60-75
20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic-Treated patients. Acta Psychiat Scand 1987; 334: 7-96
21. Max MB. Antidepressants as analgesics. In: Fields HL, Liebeskind JC, editors. Pharmacological approaches to the treatment of chronic pain: new concepts and critical issues. Seattle: IASP Press, 1994. p. 229-46
22. McCleane GJ. Does gabapentin have an analgesic effect on background, movement and referred pain? A randomized, double-blind, placebocontrolled study. Pain Clinic 2001; 13: 103-7
23. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a metaanalysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis 2010; 69: 374-9
24. Moore RA, Straube S, Derry S, McQuay HJ. Topical review: chronic low back pain analgesic studies-A methodological minefield. PAIN 2010; 149: 431-4
25. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014; 4: CD007938
26. Morlion B. Chronic low back pain: pharmacological, interventional and surgical strategies. Nature reviews. Neurology 2013; 9: 462-73
27. Moscucci M, Byrne L, Weintraub M, Cox C. Blinding, unblinding, and the placebo effect: an analysis of patients? guesses of treatment assignment in a double-blind clinical trial. Clin Pharmacol Ther 1987; 41: 259-65
28. Pandey CK, Navkar DV, Giri PJ, Raza M, Behari S, Singh RB, Singh U, Singh PK. Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar discectomy: a randomized, double blind, placebo-controlled study. J Neurosurg Anesthesiol 2005; 17: 65-8
29. Pinto RZ, Maher CG, Ferreira ML, Ferreira PH, Hancock M, Oliveira VC, McLachian AJ, Koes B. Drugs for relief of pain in patients with sciatica: systematic review and meta-Analysis. BMJ 2012; 344: e479-512
30. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. PAIN 2001; 94: 215-24
31. Roskell NS, Beard SM, Zhao Y, Le TK. A meta-Analysis of pain response in the treatment of fibromyalgia. Pain Pract 2011; 11: 516-27
32. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-42
33. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double blind, placebo-controlled trial. PAIN 2002; 99: 557-66
34. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000; 55: 915-20
35. Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010; 35: E578-85
36. Spitzer RL, Williams JB, Gibbon M, First MB. Structured clinical interview for DSM-IV. Washington: American Psychiatric Association, 1996
37. Spitzer WO, LeBlanc FE, Dupuis M. Scientific approach to the assessment and management of activity-related spinal disorder. Spine 1987; 15: 120-23
38. TaylorCP.Mechanisms of analgesia by gabapentin and pregabalin-calcium channel a2-d [Cava2-d] ligands. PAIN 2009; 142: 13-16
39. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. PAIN 2003; 106: 337-45
40. Turner JA, Denny MC. Do antidepressant medications relieve chronic low back pain? J Fam Pract 1993; 37: 545-53
41. Waddell G, Main CJ. Assessment of severity in low back disorders. Spine 1984; 9: 204-8
42. Wu YT, Lai MH, Lu SC, Chang ST. Beneficial response to gabapentin portraying with interval change of brain SPECT imaging in a case with failed back surgery syndrome. J Clin Pharm Ther 2011; 36: 525-8
43. Yaksi A, Ozgonenel L, Ozgonenel B. The efficiency of gabapentin therapy in patients with lumbar spinal stenosis. Spine 2007; 32: 939-42
44. Yildirim K, Sisecioglu M, Karatay S, Erdal A, Levent A, Ugur M, Senel K. The effectiveness of gabapentin in patients with chronic radiculopathy. Pain Clinic 2003; 15: 213-18